Usually, pituitary hormones show rebound rises exceeding the basal levels after the administration of inhibitory agents (Hall et al., 1973; Leblank et al., 1976; Leebaw et al., 1978; Kaptein et al., 1980; Hanew et al., 1984) . The postinhibitory rebound rises are considered to be a mechanism for maintaining the homeostatic hormone secretion.
In patients with prolactin (PRL) secreting pituitary adenoma (PRL-oma), defects in hypothalamic dopamine (DA) neurons and in DA receptors of tumor lactotrophs have been indicated (Fine and Frohman 1978; Bansal et al., 1981) . However, as the postinhibitory rebound increases in PRL secretion HANEW at al. Endocrinol. Japon. December 1985 are also observed in PRL-oma patients (Leblank et al., 1976; Genazzani et al., 1983) , the homeostatic PRL secretion might be present in such a pathologic state. Although PRL secretion in man may be mainly regulated by hypothalamic DA (Owens et al., 1984) , it is not clear whether DA plays a role in the postinhibitory rebound phenomenon in patients with PRL-oma. Further, the role of endogenous PRL releasing factors, e.g. TRH and VIP (vasoactive intestinal peptide), in the suppressed state of PRL secretion is a matter to be clarified (Owens et al., 1984) , although PRL-oma patients are less responsive in the basal state in their release of PRL following exogenous TRH, VIP, and DA-antagonists (Charpentier et al., 1982; Crosignani et al., 1984) .
To study the PRL secretory mechanisms in PRL-oma patients, postinhibitory rises in PRL secretion induced by DA were studied in these cases and in normal subjects. Additionally, domperidone (DA D2-receptor blocker), which does not cross the blood brain barrier (Laduron and Leysen 1979; Lazareno and Nahorsky 1982) , and TRH were employed whether or not the rebound phenomenon in PRL-oma was modified by these agents. domperidone. This suggests the importance of the rate of decreasing DA action rather than the stored PRL pool itself in inducing the postinhibitory overshoot. Therefore, the faster and greater postinhibitory PRL rises in PRL-oma patients than in normal controls may indicate the higher responsiveness of the former lactotrophs compared to the latter lactotrophs to decreasing DA action. Unlike with the single domperidone test, PRL-oma patients showed much greater PRL increments during the combination test of DA plus domperidone, whereas normal controls showed quite similar responses. In PRLoma patients, plasma PRL responses to DA-antagonists are markedly blunted when compared to normal subjects (Crosignani et al., 1984) , although the hypothalamic DA tone may be elevated in these patients (Scanlon et al., 1981; Molinatti et al., 1984) . Therefore, it seems that the lactotrophs in PRL-omas are less sensitive to endogenous DA. These findings suggest that the decreased sensitivity to DA of tumor lactotrophs was completely overcome by the large doses of DA and resulted in suppression of PRL secretion from the lactotrophs followed by an increase in releasable PRL. The increased storage of PRL in lactotrophs might bring about the rebound phenomenon and the responses of plasma PRL to domperidone. In contrast, the lactotrophs in normal subjects are very sensitive to endogenous DA and are under the tonic dopaminergic inhibition in basal state, and the blockade of such inhibition by domperidone might cause similar responses of plasma PRL regardless of the DA infusion. Accordingly, PRL secretory properties and sensitivities of lactotrophs to decreasing DA action would be quite different between PRL-oma and normal subjects. However, we should take into consideration the possibility that the differences between plasma PRL dynamics in PRL-oma and normal subjects 
